Q/C Technologies Overview
Q/C Technologies (QCLS) has a ROE of -101.68%, below the Healthcare sector average of 21.18%.
Get informed when a big investor buys or sells
+ Follow-101.68%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for QCLS is -101.68%. That is below the Healthcare sector average of 21.18%. Investors often review this figure alongside Q/C Technologies's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, QCLS currently prints -101.68% for ROE, while the sector average sits near 21.18%. That is roughly 580.0% below the sector mean. Large gaps often invite a closer look at Q/C Technologies's growth, margins, and balance sheet.
Return on Equity shows how effectively Q/C Technologies converts resources into returns. At -101.68%, QCLS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting QCLS's ROE (-101.68%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Q/C Technologies's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
